Detalhe da pesquisa
1.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366170
2.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
N Engl J Med
; 382(23): 2187-2196, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469183
3.
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
JCO Precis Oncol
; 7: e2300235, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797273
4.
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
J Clin Oncol
; 34(10): 1097-103, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858336
5.
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Leuk Res
; 50: 123-131, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27736729
6.
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
Mol Cancer Ther
; 1(7): 545-52, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12479273
7.
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
Leuk Res
; 59: 65, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28575698
8.
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.
Invest New Drugs
; 24(1): 37-77, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16380836